Medical device having a sleeve valve with bioactive agent

• US 20080086214A1
• Filed: 06/05/2007
• Published: 04/10/2008
• Est. Priority Date: 08/31/1998
• Status: Abandoned Application

• Current Assignee: Wilson-Cook Medical Incorporated (Cook Group Incorporated)
• Original Assignee: Wilson-Cook Medical Incorporated (Cook Group Incorporated)
• Inventors: Dua, Kulwinder, Hardin, David, Skerven, Gregory
• Application Number:
  US11/810,307
• Publication Number:
  US 20080086214A1
• Time in Patent Office: Days
• US Class Current: 623/23.7
• CPC Class Codes: A61F 2/04 Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts A61F2/18, A61F2/20 take precedence; devices, other than stent-grafts, providing patency to, or preventing collapsing of, tubular structures of the body other than stent-grafts, e.g. stents A61F2/82; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95
• CPC Class Codes: A61F 2/94 Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
• CPC Class Codes: A61F 2002/041 Bile ducts

Abstract

Medical devices for implantation in a body vessel are provided. A medical device can be configured as a drainage stent adapted for placement in a bodily passageway. The drainage stent preferably includes a drainage lumen extending longitudinally through the drainage stent, and a sleeve defining a collapsible lumen in fluid flow communication with the drainage lumen. The sleeve may function as a one-way valve and preferably includes a biodeposition-reducing bioactive agent, such as an antibiotic or antimicrobial agent. The medical device may be configured as a biliary or pancreatic stent.

Claims

1. A medical device for placement in a patient comprising:

a tubular member adapted for placement in a bodily passageway, the tubular member having a drainage lumen extending longitudinally through the tubular member, and a sleeve comprising a flexible material and a biodeposition-reducing bioactive agent attached to the tubular member, the sleeve defining a collapsible lumen in fluid flow communication with the drainage lumen of the drainage stent.

2. The medical device of claim 1, wherein the sleeve is moveable in response to a fluid applying a first pressure in a first direction passing the fluid through the lumen thereof, the sleeve collapsible to at least substantially close the lumen in response to either a fluid applying a second pressure in a second direction or the absence of the fluid applying a first pressure in a first direction.

3. The medical device of claim 1, wherein the drainage lumen of the drainage stent extends longitudinally from an inlet to an outlet, and the sleeve extends longitudinally from the outlet of the drainage stent.

4. The medical device of claim 1, wherein the sleeve is positioned entirely within the drainage lumen of the tubular member.

5. The medical device of claim 1, wherein the biodeposition-reducing bioactive agent is selected from the group consisting of:

an antimicrobial agent and an antibiotic agent.

6. The medical device of claim 1, wherein the biodeposition-reducing bioactive agent comprises a material selected from the group consisting of:

cephalosporins, clindamycin, chloramphenicol, carbapenems, penicillins, monobactams, quinolones, tetracycline, macrolides, sulfa antibiotics, trimethoprim, fusidic acid, aminoglycosides, vancomycin, chlorhexidine, triclosan, iodine, ampicillin, rifampin, minocycline, novobiocin, ciprofloxacin, doxycycline, amoxicillin, metronidazole, norfloxacin, ciftazidime, cefoxitin, nitrofurantoin, nitrofurazone, nidroxyzone, nifuradene, furazolidone, furaltidone, nifuroxime, nihydrazone, nitrovin, nifurpirinol, nifurprazine, nifuraldezone, nifuratel, nifuroxazide, urfadyn, nifurtimox, triafur, nifurtoinol, nifurzide, nifurfoline, nifuroquine, metallic silver, an alloy of silver containing about 2.5 wt % copper, silver citrate, silver acetate, silver benzoate, bismuth pyrithione, zinc pyrithione, zinc percarbonates, zinc perborates, bismuth salts, benzalkonium chloride (BZC), rifamycin and sodium percarbonate.

7. The medical device of claim 1, wherein sleeve comprises a material selected from the group consisting of:

expanded polytetrafluoroethylene and polyurethane.

8. The medical device of claim 1, wherein the tubular member is drainage stent.

9. The medical device of claim 1, wherein the tubular member is a biliary stent further comprising an anchoring means for securing the drainage stent within a biliary duct.

10. The medical device of claim 9, wherein the collapsible lumen of the sleeve is positioned within the drainage lumen of the biliary stent or extends from the outlet of the biliary stent.

11. The medical device of claim 1, wherein the tubular member is a biliary stent;

wherein sleeve comprises expanded polytetrafluoroethylene, the biliary stent comprises polyethylene, wherein the drainage lumen of the biliary stent extends longitudinally from an inlet to an outlet, wherein the sleeve extends longitudinally from the outlet of the drainage stent and wherein the biliary stent comprises a plurality of extending flaps positioned proximate the outlet or the inlet.

12. The medical device of claim 11, wherein the biodeposition-reducing bioactive agent is selected from the group consisting of:

cephalosporins, clindamycin, chloramphenicol, carbapenems, penicillins, monobactams, quinolones, tetracycline, macrolides, sulfa antibiotics, trimethoprim, fusidic acid, aminoglycosides, vancomycin, chlorhexidine, triclosan, iodine, ampicillin, rifampin, minocycline, novobiocin, ciprofloxacin, doxycycline, amoxicillin, metronidazole, norfloxacin, ciftazidime, cefoxitin nitrofurantoin, nitrofurazone, nidroxyzone, nifuradene, furazolidone, furaltidone, nifuroxime, nihydrazone, nitrovin, nifurpirinol, nifurprazine, nifuraldezone, nifuratel, nifuroxazide, urfadyn, nifurtimox, triafur, nifurtoinol, nifurzide, nifurfoline, nifuroquine, metallic silver, an alloy of silver containing about 2.5 wt % copper, silver citrate, silver acetate, silver benzoate, bismuth pyrithione, zinc pyrithione, zinc percarbonates, zinc perborates, bismuth salts, benzalkonium chloride (BZC), rifamycin and sodium percarbonate.

13. A drainage stent comprising:

an elongated tubular member having an exterior surface and an interior surface defining a drainage lumen extending longitudinally from an inlet to an outlet, and a sleeve comprising a flexible material and a biodeposition-reducing bioactive agent, the sleeve disposed around the outlet of the tubular drainage stent;

the sleeve extending from outlet of the tubular member and having a collapsible sleeve lumen extending longitudinally through the sleeve in fluid flow communication with the drainage lumen defined by the interior surface of the tubular member;

the sleeve being adapted to open in response to a fluid applying a first pressure in a first direction passing the fluid through the drainage lumen through the sleeve lumen; and

the sleeve further being adapted to collapse the sleeve lumen in response a fluid applying a second pressure in a second direction.

14. The drainage stent of claim 13, wherein the biodeposition-reducing bioactive agent is selected from the group consisting of:

an antimicrobial agent and an antibiotic agent.

15. The drainage stent of claim 13, wherein the biodeposition-reducing bioactive agent comprises a compound selected from the group consisting of:

cephalosporins, clindamycin, chloramphenicol, carbapenems, penicillins, monobactams, quinolones, tetracycline, macrolides, sulfa antibiotics, trimethoprim, fusidic acid, aminoglycosides, vancomycin, chlorhexidine, triclosan, iodine, ampicillin, rifampin, minocycline, novobiocin, ciprofloxacin, doxycycline, amoxicillin, metronidazole, norfloxacin, ciftazidime, cefoxitin, nitrofurantoin, nitrofurazone, nidroxyzone, nifuradene, furazolidone, furaltidone, nifuroxime, nihydrazone, nitrovin, nifurpirinol, nifurprazine, nifuraldezone, nifuratel, nifuroxazide, urfadyn, nifurtimox, triafur, nifurtoinol, nifurzide, nifurfoline, nifuroquine, metallic silver, an alloy of silver containing about 2.5 wt % copper, silver citrate, silver acetate, silver benzoate, bismuth pyrithione, zinc pyrithione, zinc percarbonates, zinc perborates, bismuth salts, benzalkonium chloride (BZC), rifamycin and sodium percarbonate.

16. The medical device of claim 13 configured as a drainage stent adapted for placement within a biliary or pancreatic duct, the drainage stent comprising polyethylene or polyurethane.

17. The drainage stent of claim 16, wherein the biodeposition-reducing bioactive agent comprises a compound selected from the group consisting of:

cephalosporins, clindamycin, chloramphenicol, carbapenems, penicillins, monobactams, quinolones, tetracycline, macrolides, sulfa antibiotics, trimethoprim, fusidic acid, aminoglycosides, vancomycin, chlorhexidine, triclosan, iodine, ampicillin, rifampin, minocycline, novobiocin, ciprofloxacin, doxycycline, amoxicillin, metronidazole, norfloxacin, ciftazidime, cefoxitin, nitrofurantoin, nitrofurazone, nidroxyzone, nifuradene, furazolidone, furaltidone, nifuroxime, nihydrazone, nitrovin, nifurpirinol, nifurprazine, nifuraldezone, nifuratel, nifuroxazide, urfadyn, nifurtimox, triafur, nifurtoinol, nifurzide, nifurfoline, nifuroquine, metallic silver, an alloy of silver containing about 2.5 wt % copper, silver citrate, silver acetate, silver benzoate, bismuth pyrithione, zinc pyrithione, zinc percarbonates, zinc perborates, bismuth salts, benzalkonium chloride (BZC), rifamycin and sodium percarbonate.

18. A method of treating a condition associated with reduced fluid flow through a body vessel, the method comprising the steps of:

providing a drainage stent comprising a tubular member having an exterior surface and an interior surface defining a drainage lumen extending along the longitudinal axis of the tubular member from an inlet to an outlet, and a sleeve extending longitudinally from the outlet, the sleeve comprising a biodeposition-reducing bioactive agent and defining a collapsible lumen in fluid flow communication with the drainage lumen defined by the interior surface of the tubular member; and

implanting the drainage stent within a body vessel.

19. The method of claim 18, wherein the condition is selected from the group consisting of:

obstructive jaundice, postoperative biliary stricture, primary sclerosing cholangitis and chronic pancreatitis.

20. The method of claim 18, wherein the tubular member comprises polyethylene and the sleeve comprises expanded polytetrafluoroethylene;

and wherein the biodeposition-reducing bioactive agent comprises a compound selected from the group consisting of;

cephalosporins, clindamycin, chloramphenicol, carbapenems, penicillins, monobactams, quinolones, tetracycline, macrolides, sulfa antibiotics, trimethoprim, fusidic acid, aminoglycosides, vancomycin, chlorhexidine, triclosan, iodine, ampicillin, rifampin, minocycline, novobiocin, ciprofloxacin, doxycycline, amoxicillin, metronidazole, norfloxacin, ciftazidime, cefoxitin, nitrofurantoin, nitrofurazone, nidroxyzone, nifuradene, furazolidone, furaltidone, nifuroxime, nihydrazone, nitrovin, nifurpirinol, nifurprazine, nifuraldezone, nifuratel, nifuroxazide, urfadyn, nifurtimox, triafur, nifurtoinol, nifurzide, nifurfoline, nifuroquine, metallic silver, an alloy of silver containing about 2.5 wt % copper, silver citrate, silver acetate, silver benzoate, bismuth pyrithione, zinc pyrithione, zinc percarbonates, zinc perborates, bismuth salts, benzalkonium chloride (BZC), rifamycin and sodium percarbonate.